Last reviewed · How we verify

NCT03487484

Quality of Life in Patients With Rectal Cancer Receiving Total Mesorectal Excision With or Without Stoma

Terminated Last updated 10 April 2020
What this trial tests

trial testing Quality of Life Questionnaire for gastrointestinal tract in Rectal Cancer in 5 participants. Terminated before completion.

Timeline
22 March 2018
Primary endpoint
22 March 2020
22 March 2020

Quick facts

Lead sponsorUniversity Hospital, Basel, Switzerland
StatusTerminated
Study typeOBSERVATIONAL
Enrollment5
Start date22 March 2018
Primary completion22 March 2020
Estimated completion22 March 2020
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Basel, Switzerland

Who can join

18 and older, any sex, with Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal is to evaluate whether the renunciation of a diverting stoma in patients with adjuvant chemotherapy after low anterior resection with total mesorectal excision (TME) and neoadjuvant chemoradiotherapy leads to a better quality of life without increasing morbidity and mortality in patients with rectal cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03487484.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing